US58933Y1055 - Common Stock
MERCK & CO. INC.
NYSE:MRK (11/21/2024, 10:42:09 AM)
97.76
+0.32 (+0.33%)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 72,000 full-time employees. The company offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The company sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.
MERCK & CO. INC.
126 East Lincoln Avenue
Rahway NEW JERSEY 07033
P: 19087404000
CEO: Kenneth C. Frazier
Employees: 71000
Website: https://www.merck.com/
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.
Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting from Beijing’s campaign to drive down medical costs.
Here you can normally see the latest stock twits on MRK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: